244 related articles for article (PubMed ID: 33651713)
1. Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model.
Howard ZM; Dorn LE; Lowe J; Gertzen MD; Ciccone P; Rastogi N; Odom GL; Accornero F; Chamberlain JS; Rafael-Fortney JA
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33651713
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy.
Parvatiyar MS; Brownstein AJ; Kanashiro-Takeuchi RM; Collado JR; Dieseldorff Jones KM; Gopal J; Hammond KG; Marshall JL; Ferrel A; Beedle AM; Chamberlain JS; Renato Pinto J; Crosbie RH
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039133
[TBL] [Abstract][Full Text] [Related]
3. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy.
Bostick B; Shin JH; Yue Y; Wasala NB; Lai Y; Duan D
J Mol Cell Cardiol; 2012 Aug; 53(2):217-22. PubMed ID: 22587991
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy.
Meyers TA; Townsend D
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443395
[TBL] [Abstract][Full Text] [Related]
5. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure.
Townsend D; Blankinship MJ; Allen JM; Gregorevic P; Chamberlain JS; Metzger JM
Mol Ther; 2007 Jun; 15(6):1086-92. PubMed ID: 17440445
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
7. A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic
Wong TWY; Ahmed A; Yang G; Maino E; Steiman S; Hyatt E; Chan P; Lindsay K; Wong N; Golebiowski D; Schneider J; Delgado-Olguín P; Ivakine EA; Cohn RD
Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32988972
[TBL] [Abstract][Full Text] [Related]
8. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.
Jearawiriyapaisarn N; Moulton HM; Sazani P; Kole R; Willis MS
Cardiovasc Res; 2010 Feb; 85(3):444-53. PubMed ID: 19815563
[TBL] [Abstract][Full Text] [Related]
9. Uniform low-level dystrophin expression in the heart partially preserved cardiac function in an aged mouse model of Duchenne cardiomyopathy.
Wasala NB; Yue Y; Vance J; Duan D
J Mol Cell Cardiol; 2017 Jan; 102():45-52. PubMed ID: 27908661
[TBL] [Abstract][Full Text] [Related]
10. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.
Echigoya Y; Nakamura A; Nagata T; Urasawa N; Lim KRQ; Trieu N; Panesar D; Kuraoka M; Moulton HM; Saito T; Aoki Y; Iversen P; Sazani P; Kole R; Maruyama R; Partridge T; Takeda S; Yokota T
Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4213-4218. PubMed ID: 28373570
[TBL] [Abstract][Full Text] [Related]
11. Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
Razzoli M; Lindsay A; Law ML; Chamberlain CM; Southern WM; Berg M; Osborn J; Engeland WC; Metzger JM; Ervasti JM; Bartolomucci A
EBioMedicine; 2020 May; 55():102700. PubMed ID: 32192914
[TBL] [Abstract][Full Text] [Related]
12. Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy.
Townsend D; Yasuda S; Chamberlain J; Metzger JM
Trends Cardiovasc Med; 2009 Feb; 19(2):50-55. PubMed ID: 19577712
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
[TBL] [Abstract][Full Text] [Related]
14. Enhanced dimethylarginine degradation improves coronary flow reserve and exercise tolerance in Duchenne muscular dystrophy carrier mice.
Garbincius JF; Merz LE; Cuttitta AJ; Bayne KV; Schrade S; Armstead EA; Converso-Baran KL; Whitesall SE; D'Alecy LG; Michele DE
Am J Physiol Heart Circ Physiol; 2020 Sep; 319(3):H582-H603. PubMed ID: 32762558
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease.
Eren SA; Tastan C; Karadeniz KB; Turan RD; Cakirsoy D; Kancagi DD; Yilmaz SU; Oztatlici M; Oztatlici H; Ozer S; Tumentemur G; Baykal AT; Ovali E
Curr Gene Ther; 2023; 23(4):304-315. PubMed ID: 37032509
[TBL] [Abstract][Full Text] [Related]
16. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.
Rodino-Klapac LR; Janssen PM; Montgomery CL; Coley BD; Chicoine LG; Clark KR; Mendell JR
J Transl Med; 2007 Sep; 5():45. PubMed ID: 17892583
[TBL] [Abstract][Full Text] [Related]
17. Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.
Chun JL; O'Brien R; Song MH; Wondrasch BF; Berry SE
Stem Cells Transl Med; 2013 Jan; 2(1):68-80. PubMed ID: 23283493
[TBL] [Abstract][Full Text] [Related]
18. Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.
Betts CA; Saleh AF; Carr CA; Hammond SM; Coenen-Stass AM; Godfrey C; McClorey G; Varela MA; Roberts TC; Clarke K; Gait MJ; Wood MJ
Sci Rep; 2015 Mar; 5():8986. PubMed ID: 25758104
[TBL] [Abstract][Full Text] [Related]
19. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
[TBL] [Abstract][Full Text] [Related]
20. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice.
van Putten M; Hulsker M; Young C; Nadarajah VD; Heemskerk H; van der Weerd L; 't Hoen PA; van Ommen GJ; Aartsma-Rus AM
FASEB J; 2013 Jun; 27(6):2484-95. PubMed ID: 23460734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
